NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee D) meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 2 September 2020

**Location:** Via Zoom

## Committee members present:

1. Professor Gary McVeigh [Chair] Present for all items
2. Dr Lindsay Smith [Vice Chair] Present for all items
3. James Avery Present for all items
4. Dr Nabeel Alsindi Present for items
5. Dr Matt Bradley Present for all items
6. Sofia Diaz Present for items 3 to 3.4.2
7. Professor Rachel Elliott Present for all items
8. Gillian Ells Present for all items
9. Professor Paula Ghaneh Present for all items
10. Dr Rebecca Harmston Present for all items
11. Dr Andrew Hitchings Present for items 1 to 2.3.2
12. Dr Robert Hodgson present for items 3 to 3.4.2
13. Dr Bernard Khoo Present for all items
14. Dr Soo Fon Lim Present for all items
15. Dr Guy Makin Present for items 1 to 2.3.2
16. Amanda Matse-Orere Present for items 1 to 2.3.2
17. Giles Monnickendam Present for all items
18. Malcolm Oswald Present for all items
19. Baljit Singh Present for all items

## External group representatives present:

Robert Hodgson, NHS Centre for Reviews & Dissemination, and centre for Health Economics, Present for items 1 to 2.2

Nick Meader, NHS Centre for Reviews & Dissemination, and centre for Health Economics, Present for items 1 to 2.2

Peter Murphy, NHS Centre for Reviews & Dissemination, and centre for Health Economics, Present for items 1 to 2.2

Ewen Cummins, Peninsula Technology Assessment Group. University of Exeter, Present for items 3 to 3.3.1

G.J Melendez-Torres, Peninsula Technology Assessment Group. University of Exeter, Present for items 3 to 3.3.1

## Professional experts present:

Dr Nicola Giffin, Clinical expert, Consultant Neurologist, Chair of ABN advisory group on headache and pain, Present for items 1 to 2.2

Ria Bhola, Patient Expert, nominated by the Migraine Trust, Present for items 1 to 2.2

Brenda Weatherill, Patient Expert, nominated by the Migraine Trust, Present for items 1 to 2.2

## Introduction to the meeting

The chair welcomed members of the committee and other attendees present to the meeting.

## Appraisal of Galcanezumab for preventing migraine [ID1372]

### Part 1 – Open session

The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Eli Lilly and Company.

The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Giles Monnickendam declared an indirect non-financial interest as his employer [Vitaccess] is designing and conducting an observational study for Teva, involving the migraine indication and fremanezumab.
* It was agreed that Giles’s declaration would not prevent him from participating in this section of the meeting.
* Dr Nicola Giffin declared direct and indirect financial interests as she has received an honorarium [2018] from Novartis who market erenumab and has received travel, hospitality, and conference fees [2019] from Teva who market fremanezumab.
* It was agreed that Nicola’s declarations would not prevent her from participating in this section of the meeting.
* No further conflicts or interest were declared for this appraisal

The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.

### Part 2 –Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]

The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached through a vote by members..

The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Upadacitinib for previously treated severe active rheumatoid arthritis [ID1400]

### Part 1 – Open session

The chair welcomed the invited assesment group representatives, members of the public and company representatives from Abbvie.

The chair asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Matt Bradley declared a non-financial and personal interest as his company is developing a medicine for rheumatoid arthritis. Due to the timings of the work and the timelines for the related NICE appraisals he feels it is unlikely that he or the company can benefit from any knowledge gained from this appraisal.
* It was agreed that Matt’s declaration would not prevent him from participating in this section of the meeting.
* No further conflicts of interest were declared for this item.

The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.

### Part 2a – Closed session [members of the public and the company were asked to leave the meeting].

The committee discussed confidential information submitted for this item.

### Part 2b –Closed session [external group representatives were asked to leave the meeting].

The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.

The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Date of the next meeting

The next meeting of the Technology Appraisal (Committee D) will be held on Tuesday 6 October 2020 and will start promptly at 09:30am.